Golf Tournament 2012

Annual Golf Tournament


The First Annual Sharon Leigh Cancer Organization Golf Tournament

Sharon with Kelli and Mike from Cedar-Sinai
Was an amazing success!
The fundraising effort was very successful and lots of fun was had by everyone. We can't wait until next year!

June 29, 2012 proved to be an incredibly successful fundraising event considering the fact that the tournament, held at Monarch Dunes, was a first time happening. The tournament, the committee, and sponsors were able to raise over $40,000. The purpose of the tournament is for awareness and research for early detection of Ovarian cancer.

This was our signature fundraiser benefiting Cedars Sinai ovarian research.
(Listen to Sharon discuss the golf tournament on the Dave Congalton Show by clicking here)



Photos from the golf tournament:

Booklet Cover



One of the Tables

What a Beautiful Day

Getting Started

Checking it Out

Riding in Style

Closest to the Hole

Having Fun

Great Form

A Few Moments to Chat

The Winners

Our souvenir cups

The Raffle

The Wine

The Drawing

(note: below is our letter about the tournament, if you missed it but would still like to donate to help fund early detection of ovarian cancer click the button to the left, or read below.) 

Dear Friend:
If you thought you could perhaps help some of the 70% of women (wives, sisters, daughters, granddaughters) currently diagnosed with ovarian cancer too late to be saved, would you do it?

Ovarian cancer is the deadliest of the gynecological cancers, causing more deaths in the U.S. each year than all other gynecological cancers combined. The five-year survival rate is over 90% and long-term prognosis is good for those women diagnosed with ovarian cancer in Stage 1.

But only 30% of women diagnosed are still in Stage 1. The Sharon Leigh Cancer Organization, Inc., a nonprofit, was created on the Central California Coast to raise research funds and spread the word about the importance of early detection for ovarian cancers.

Now you can help increase the chances that women will benefit from early detection and that research break-throughs for ovarian cancer will emerge. The Sharon Leigh Cancer Organization is establishing its first outreach effort and fundraiser. An estimated 25,000 Central Coast women will be educated about the benefits of early detection of ovarian cancer through promotion of the event. Net proceeds from the inaugural fundraiser will benefit Cedars-Sinai ovarian research. Cedars-Sinai is a national leader in research supporting early detection of women’s cancers.

The First Annual “Ovarian Cancer Benefit Golf Tournament”, hosted by the Sharon Leigh Cancer Organization, will take place Friday, June 29, 2012, at the Monarch Dunes Golf Course. We ask that you consider helping us increase the number of women diagnosed with ovarian cancer in time for effective treatment. Please consider a donation to the Sharon Leigh Cancer Organization or a sponsorship for the First Annual Ovarian Cancer Benefit Golf Tournament.

Sharon Rude, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
(805) 473-8980

Tuesday, April 21, 2015
English Facebook Spanish Facebook Group English Facebook Group Twitter Ovarian Cancer Google+

Want to stay informed?

Up-to-date info on Ovarian Cancer

Like our Facebook page. Everyday we post the most recent breakthroughs and human interest stories on Ovarian Cancer.

Latest News

Information about ovarian cancer symptoms and treatments. Explore the latest medical research on ovarian cysts and ovarian cancer including including stages of the disease and new treatment options.
  • Successful ovarian cancer treatment often relies on catching it early. A study may help point to a new method for women at risk.
  • Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute presented today at the American Association for Cancer Research Annual Meeting 2015.
  • Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology.
  • Scientists have uncovered patterns of DNA anomalies that predict a woman's outcome significantly better than tumor stage. In addition, these patterns are the first known indicator of how well a woman will respond to platinum therapy. The patterns were discovered by using a new mathematical technique in the analysis of DNA profiles from the Cancer Genome Atlas, a national database containing data from hundreds of ovarian cancer patients.
  • Recent media attention has focused on American actress Angelina Jolie's decision to have her ovaries and fallopian tubes surgically removed after genetic testing for such cancers. A study suggests that all women with ovarian cancer should be tested for these genes, regardless of their family history. The findings have clinical implications both for the treatment of this disease and for the screening of individuals at-risk.
  • A mother who has tested positive for the BRCA2 cancer gene is one of 12 people in her family over three generations linked to the gene or diagnosed with cancer. Now she is using her family’s genetic history to contribute to cancer research, prevention and treatment – with the aim of improving the quality of life for those facing hereditary risk.
  • Researchers have identified mutations that are associated with significantly different risks of breast and ovarian cancers. Authors say the results -- which show that some mutations confer higher risks of breast cancer, while other mutations show higher risks of ovarian cancer -- may lead to more effective cancer risk assessment, care and prevention strategies for health care providers and carriers.
  • Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman’s tumor and extend the time period between initial treatment and the cancer’s return.
  • Overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.